It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Blood-brain barrier (BBB) breakdown and immune cell infiltration into the central nervous system (CNS) are early hallmarks of multiple sclerosis (MS). High numbers of CD8+ T cells are found in MS lesions, and antigen (Ag) presentation at the BBB has been proposed to promote CD8+ T cell entry into the CNS. Here, we show that brain endothelial cells process and cross-present Ag, leading to effector CD8+ T cell differentiation. Under physiological flow in vitro, endothelial Ag presentation prevented CD8+ T cell crawling and diapedesis resulting in brain endothelial cell apoptosis and BBB breakdown. Brain endothelial Ag presentation in vivo was limited due to Ag uptake by CNS-resident macrophages but still reduced motility of Ag-specific CD8+ T cells within CNS microvessels. MHC class I-restricted Ag presentation at the BBB during neuroinflammation thus prohibits CD8+ T cell entry into the CNS and triggers CD8+ T cell-mediated focal BBB breakdown.
Blood-brain barrier (BBB) breakdown and immune cell infiltration into the central nervous system are early hallmarks of multiple sclerosis. Here, the authors demonstrate that brain endothelial cells cross-present antigen to CD8+ T cells, thereby preventing their migration and initiating BBB breakdown.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University of Bern, Theodor Kocher Institute, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
2 University of Bern, Institute of Pathology, Experimental Pathology, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
3 University and University Hospitals of Geneva, Department of Pathology and Immunology, Division of Clinical Pathology, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812)
4 University of Toulouse, CNRS, INSERM, UPS, Toulouse Institute for infectious and inflammatory diseases, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X)
5 University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484)
6 University of Lübeck, Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672)
7 Mayo Clinic, Mayo Clinic Graduate School of Biomedical Sciences, College of Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)